Anivive is reinventing the drug development process in pet pharma with a pipeline of 8+ first-in-class pharmaceuticals, biologics, and vaccines. Our proprietary software accelerates the delivery of breakthrough treatments for pets’ biggest unmet medical needs. Anivive’s LAVERDIA™-CA1 (verdinexor) is the first conditionally approved oral tablet to treat canine lymphoma.
To learn more visit: www.anivive.com.
Address3750 Schaufele Avenue